Market research
6L7A.F Bellerophon Therapeutics, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- 25
- Dividend yield
- 0.0%
- Beta
- 0.55
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US0787713009
- Market cap
- 5M
- P/E ratio
- Not available
- Analyst target
- 25
- Dividend yield
- 0.0%
- Beta
- 0.55
About
About Bellerophon Therapeutics, Inc
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse, which is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 6L7A.F discussion.
5 years, 5 months ago
Bellerophon Therapeutics, Inc is currently in a long term downtrend where the price is trading 32.2% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Bellerophon Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 96.2% to $-8M since the same quarter in the previous year.
Finally, its free cash flow fell by 121.3% to $-6M since the same quarter in the previous year.
Based on the above factors, Bellerophon Therapeutics, Inc gets an overall score of 1/5.